Stewart, Jacob R <br/><br/>
Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review.  [electronic resource] 

 -  European journal of dermatology : EJD  Dec 2018 
 - 764-774 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Systematic Review 
<br/><br/><label>ISSN: </label>1952-4013 
<br/><br/><label>Standard No.: </label>10.1684/ejd.2018.3444  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alemtuzumab--therapeutic use<br/>Aminopterin--analogs & derivatives<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Deoxycytidine--analogs & derivatives<br/>Folic Acid Antagonists--therapeutic use<br/>Humans<br/>Mycosis Fungoides--drug therapy<br/>Retreatment<br/>Sezary Syndrome--drug therapy<br/>Skin Neoplasms--diagnostic imaging<br/>Gemcitabine